Log in to search using one of your social media accounts:

 

Aranesp (Darbepoetin Alfa) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 22, 2017 Category: Drugs & Pharmacology Source Type: news

Amgen And DaVita Enter Into New Sourcing And Supply Agreement
THOUSAND OAKS, Calif., Jan. 9, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced it has entered into a six-year Sourcing and Supply Agreement with DaVita Inc.  This is a continuation of Amgen's long-term relationship with DaVita that is focused on serving dialysis patients. Under the terms of the new agreement, Amgen will supply DaVita with EPOGEN® (epoetin alfa) and Aranesp® (darbepoetin alfa) in amounts necessary to meet a specified annual percentage of DaVita's and its affiliates' requirements for erythropoiesis-stimulating agents used in providing dialysis services in the United States and Puerto...
Source: Amgen News Release - January 9, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Highlights Data To Be Presented At 21st Congress Of The European Hematology Association
BLINCYTO® (Blinatumomab) TOWER Study Demonstrates Improved Overall Survival Versus Standard of Care in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia TOWER Study to be Presented at Presidential Symposium as a Best Abstract Sub-group Analyses From Pivotal Head-To-Head Phase 3 Studies Provide Further Insight Into Kyprolis® (Carfilzomib) as Treatment Option for Patients With Multiple Myeloma Aranesp® (Darbepoetin Alfa) Phase 3 ARCADE Data Demonstrates Significant Reduction in Red Blood Cell Transfusions in Anemic Patients With Myelodysplastic Syndrome THOUSAND OAKS, Calif., May 19, 2016 /PR...
Source: Amgen News Release - May 19, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen's First Quarter 2016 Revenues Increased 10 Percent To $5.5 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $2.90
First Quarter 2016 GAAP EPS Were $2.50 2016 Total Revenues and Adjusted EPS Guidance Increased to $22.2-$22.6 Billion and $10.85-$11.20, Respectively THOUSAND OAKS, Calif., April 28, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2016. Key results include: Total revenues increased 10 percent versus the first quarter of 2015 to $5,527 million, with 7 percent product sales growth driven by Enbrel® (etanercept), Prolia® (denosumab), Aranesp® (darbepoetin alfa), Neulasta® (pegfilgrastim), Kyprolis® (carfilzomib) and XGEVA® (denosumab). A...
Source: Amgen News Release - April 28, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Why Your Oncologist Might Prescribe Procrit or...
Learn why doctors prescribe Procrit and Aranesp to boost red cell production in breast cancer patients who have anemia after undergoing chemotherapy. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - April 18, 2016 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

How are Procrit & Aranesp Used to Treat...
Procrit and Aranesp help boost red cell production for breast cancer patients who have anemia after undergoing chemotherapy. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - March 28, 2016 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Phase 3 Study Demonstrates Aranesp® (Darbepoetin Alfa) Reduces Red Blood Cell Transfusions In Patients With Myelodysplastic Syndrome (MDS)
First Phase 3 Data From Placebo-Controlled Study With an Erythropoiesis-Stimulating Agent (ESA) in Anemic Patients With MDS Study Met Primary Endpoint and Key Secondary Endpoint of Erythroid Response THOUSAND OAKS, Calif., Feb. 15, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the randomized, double-blind, placebo-controlled Phase 3 Aranesp® (darbepoetin alfa) ARCADE trial met its primary endpoint of reducing the incidence of red blood cell transfusions in anemic patients with low and intermediate-1 risk MDS at the end of the blinded 25-week study period. Aranesp also significantly improved ...
Source: Amgen News Release - February 15, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

​Amgen to pay $71 million to settle claims of off-label drug uses
Biotechnology company Amgen Inc. has agreed to pay $71 million to 48 states and the District of Columbia to settle claims that it improperly promoted its top-selling drugs, Aranesp and Enbrel, for uses not approved by the Food and Drug Administration. California will receive $4.6 million from the settlement, Attorney General Kamala Harris announced Tuesday. Harris and the other attorneys general alleged that Amgen (Nasdaq: AMGN) violated state consumer protection laws by promoting Aranesp for dosing… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 19, 2015 Category: Pharmaceuticals Source Type: news

Texas to share in $71M California pharma company settlement
The State of Texas will build up its bank account as a result of Thousand Oaks, California-based Amgen Inc.’s decision to settle a multi-state investigation stemming from allegations it unlawfully promoted biologic medications Aranesp and Enbrel for off-label uses. Amgen has agreed to pay $71 million to 49 states, including Texas, to resolve the matter, according to Texas Attorney General Ken Paxton. Texas’ share of the settlement is $4.3 million. Aranesp is a treatment for anemia, and Enbrel… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 19, 2015 Category: Pharmaceuticals Authors: W. Scott Bailey Source Type: news

Amgen Pays $71 Mln to Settle Enbrel, Aranesp Marketing CaseAmgen Pays $71 Mln to Settle Enbrel, Aranesp Marketing Case
Amgen Inc has reached a $71 million settlement with 48 states and the District of Columbia to resolve claims that the company promoted its drugs Enbrel and Aranesp for uses not approved by the FDA. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 19, 2015 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Amgen to Pay $71M to Settle Off-Label Enbrel, Aranesp Claims
California-based biotech Amgen has agreed to pay $71 million to resolve claims that the company promoted its popular Enbrel and Aranesp drugs for uses not approved by the FDA. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 19, 2015 Category: Pharmaceuticals Source Type: news

Hawaii to receive $800k of $71M settlement with drugmaker Amgen
Hawaii will receive $800,000 as part of a $71 million multi-state settlement with Amgen Inc. over the marketing claims about the drugs Aranesp and Enbrel. The state will share the settlement with 47 other states and the District of Columbia, officials with the state Department of Commerce and Consumer Affairs’ Office of Consumer Protection said. The allegations against Amgen Inc. (Nasdaq: AMGN) involve accusations that Amgen promoted Aranesp, which is use to treat anemia, for dosing frequencies… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 19, 2015 Category: American Health Source Type: news

Washington state gets a share of $71M multi-state settlement with Amgen over drug marketing
Oregon Attorney General Ellen Rosenblum took the lead in a multi-state $71 million settlement with drug maker Amgen Inc. in connection with its promotion of two medications. The settlement resolves allegations that Amgen unlawfully promoted Aranesp and Enbrel. Aranesp is used to treat certain types of anemia by stimulating bone marrow to produce red blood cells. Enbrel is used to treat plaque psoriasis, among other conditions. Read the judgment document below. Specifically, the Complaint and… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 18, 2015 Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news

Texas to share in $71M California pharma company settlement
The State of Texas will build up its bank account as a result of Thousand Oaks, California-based Amgen Inc.’s decision to settle a multi-state investigation stemming from allegations it unlawfully promoted biologic medications Aranesp and Enbrel for off-label uses. Amgen has agreed to pay $71 million to 49 states, including Texas, to resolve the matter, according to Texas Attorney General Ken Paxton. Texas’ share of the settlement is $4.3 million. Aranesp is a treatment for anemia, and Enbrel… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 18, 2015 Category: Pharmaceuticals Authors: W. Scott Bailey Source Type: news

Amgen Reaches $71 Million Settlement With States
Amgen Inc. reached a $71 million settlement with 48 states related to allegations that the biotechnology company made unsubstantiated marketing claims about blockbuster drugs Aranesp and Enbrel, according to the New York attorney general’s office. (Source: WSJ.com: Health)
Source: WSJ.com: Health - August 18, 2015 Category: Pharmaceuticals Tags: PAID Source Type: news

ARANESP (Darbepoetin Alfa) Injection, Solution ARANESP (Darbepoetin Alfa) Solution [Amgen Inc]
Updated Date: Mar 11, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - March 11, 2015 Category: Drugs & Pharmacology Source Type: news

Express Scripts Drops Amgen Anemia Drugs From FormularyExpress Scripts Drops Amgen Anemia Drugs From Formulary
Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, said on Friday it will remove an additional 25 products from its list of preferred drugs in 2015, including anemia drugs Epogen and Aranesp. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 5, 2014 Category: Consumer Health News Tags: Internal Medicine News Source Type: news

Express Scripts drops Amgen anemia drugs from formulary
(Reuters) - Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, on Friday said it will remove 25 products from its 2015 list of preferred drugs, including anemia treatments Epogen and Aranesp, both sold by Amgen Inc. (Source: Reuters: Health)
Source: Reuters: Health - August 1, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Cipla partners with Hetero to launch biosimilar anaemia drug
Actorise is a biosimilar of 'Darbepoetin alfa', which is marketed by US-based Amgen under the brand Aranesp. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 19, 2014 Category: Pharmaceuticals Source Type: news

Aranesp - Darbepoetin Alfa – Drug To...
Aranesp (darbepoetin alfa) is a drug given to patients who have chemotherapy-induced anemia (low red blood cell count). An injection of Aranesp stimulates red blood cell production, with a synthetic version of erythropoietin, a protein made in your kidneys. Learn about how it works, possible side effects, and recommendations during treatment. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - February 26, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Amgen settles kickback allegations with $24.9m settlement
Amgen has settled allegations that it provided kickbacks to long-term care pharmacy providers to encourage them to use its Aranesp anaemia drug instead of a rival's, by agreeing to pay $24.9m, the US Department of Justice (DOJ) announced this week. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 18, 2013 Category: Pharmaceuticals Source Type: news

Amgen to pay $25 million to settle kickback allegations
(Reuters) - Amgen Inc has agreed to pay $24.9 million to settle allegations that it provided kickbacks to long-term care pharmacy providers to entice them to use its Aranesp anemia drug instead of a rival medicine, the Department of Justice announced on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - April 16, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Findings Do Not Support The Use Of Darbepoetin Alfa To Treat Anemic Heart Failure Patients
Researchers from Sahlgrenska Academy, University of Gothenburg, Sweden, have found that a commonly used drug to treat anemia in heart failure patients does not improve patients' health, nor does it reduce their risk of death from heart failure. Results of the international study were presented at the American College of Cardiology's annual meeting in San Francisco and published simultaneously online by The New England Journal of Medicine... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 14, 2013 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

Treatment of anaemia with darbepoetin alfa in systolic heart failure
Source: New England Journal of Medicine Area: News The findings of a study evaluating whether darbepoetin alfa improves clinical outcomes in patients with chronic systolic heart failure and non-iron-deficiency anaemia have been presented at the meeting of the American College of Cardiology and published early online in the New England Journal of Medicine.   The authors note that there is evidence to suggest that increasing haemoglobin (Hb) level with the use of erythropoiesis-stimulating agents (ESAs) may improve outcomes in patients with heart failure and anaemia, but it is not robust. Their study (Reduction of ...
Source: NeLM - Cardiovascular Medicine - March 11, 2013 Category: Cardiology Source Type: news

Cleveland Clinic research shows anemia drug does not improve health of anemic heart failure patients
(Cleveland Clinic) Researchers from Cleveland Clinic and Sweden-based Sahlgrenska University Hospital have found that a commonly used drug to treat anemia in heart failure patients -- darbepoetin alfa -- does not improve patients' health, nor does it reduce their risk of death from heart failure. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 10, 2013 Category: Global & Universal Source Type: news

Amgen Phase 3 Aranesp RED-HF trial fails to meet primary endpoint
Amgen has reported that Phase 3 Aranesp (darbepoetin alfa) RED-HF (reduction of events with darbepoetin alfa in heart failure) trial did not meet the primary endpoint of reducing the composite endpoint of time to death from any cause or first hospita… (Source: Drug Development Technology)
Source: Drug Development Technology - January 18, 2013 Category: Pharmaceuticals Source Type: news

Patients with HF failed to benefit from Aranesp
(Source: HemOncToday.com)
Source: HemOncToday.com - January 18, 2013 Category: Cancer & Oncology Source Type: news

Darbepoetin Alfa Disappoints in RED-HFDarbepoetin Alfa Disappoints in RED-HF
Sponsors for the RED-HF trial say no new safety concerns arose with the drug, but treatment had no benefit over placebo in terms of reducing death from any cause or first hospital admission for worsening HF in patients with left ventricular systolic dysfunction and anemia. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 17, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Aranesp Fails in RED-HF Trial
(MedPage Today) -- The RED-HF trial, testing darbepoetin alfa (Aranesp) in heart failure patients with anemia, failed to meet its primary endpoint, according to top-line results released by Amgen. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 17, 2013 Category: Cardiology Source Type: news

Darbepoetin alfa disappoints in RED-HF
Sponsors for the RED-HF trial say no new safety concerns arose with the drug, but treatment had no benefit over placebo in terms of reducing death from any cause or first hospital admission for worsening HF in patients with left ventricular systolic dysfunction and anemia. (Source: theHeart.org)
Source: theHeart.org - January 17, 2013 Category: Cardiology Source Type: news

Phase III trial of darbepoetin alfa (Aranesp) in heart failure fails to meet primary efficacy endpoint
Source: PharmaLive Area: News Amgen has announced that its phase III Aranesp® (darbepoetin alfa) RED-HF® (Reduction of Events With Darbepoetin Alfa in Heart Failure) trial has failed to meet its primary efficacy endpoint.   The trial was initiated in 2006, and recruited 2278 patients with symptomatic systolic heart failure and anaemia (haemoglobin 9.0 to 12.0 g/dL) who were randomised to receive either treatment with darbepoetin to achieve a target haemoglobin of at least 13.0 g/dL (not to exceed 14.5 g/dL), or placebo. The study primary endpoint was a reduction in the composite endpoint of time to death ...
Source: NeLM - Cardiovascular Medicine - January 17, 2013 Category: Cardiology Source Type: news

Amgen Trial Fails To Show Benefit Of Anemia Drug In Heart Failure Patients
The bad news continues for Aranesp (darbepoetin alfa), Amgen's long-acting erythropoietin-stimulating agent. The drug is intended to stimulate red cell blood production in patients with anemia. Amgen today announced the top line results of a large phase 3 heart failure trial of the drug and said  the trial had failed to meet its primary endpoint. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 16, 2013 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

ARANESP (Darbepoetin Alfa) Solution ARANESP (Darbepoetin Alfa) Injection, Solution [Amgen Inc]
Updated Date: Jan 7, 2013 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - January 7, 2013 Category: Drugs & Pharmacology Source Type: news

NCCN Updates Cancer- and Treatment-Related Anemia Guidelines
FORT WASHINGTON, Pa., December 20, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Cancer- and Treatment-Related Anemia Guidelines relating to the use of erythropoietin-stimulating agents (ESAs), such as epoetin alfa and darbepoetin alfa. ESAs are no longer recommended for the treatment of cancer-related anemia associated with solid tumors or hematologic malignancies other than myelodysplastic syndromes (MDS). ESA therapy is an option for patient... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - December 20, 2007 Category: Cancer & Oncology Source Type: news

NCCN Updates Cancer- and Treatment-Related Anemia Guidelines
JENKINTOWN, Pa., March 5, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Cancer- and Treatment-Related Anemia Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings. A significant issue the panel addressed was the results of a trial by Amgen, Inc. studying the use of Aranesp (darbepoetin alfa)... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - March 5, 2007 Category: Cancer & Oncology Source Type: news